id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-D-0880-0036,FDA,FDA-2012-D-0880,Assessing User Fees Under the Generic Drug User Fee Amendments of 2017; Draft Guidance for Industry; Final Guidance,Other,Guidance,2023-06-08T04:00:00Z,2023,6,2023-06-08T04:00:00Z,,2024-11-11T21:23:32Z,,1,0,0900006485ae0c44